Accurate cancer screening is crucial for
managing cancer as a chronic disease
Target therapy
Liquid biopsy for drug
resistance of target therapy
The only commercially available ability to identify and capture circulating cancer cell masses (CTM), combined with single-cell NGS, or ddPCR), increases the resolution of traditional MRD using ctDNA detection and improves the sensitivity of tumor recurrence detection.
Combination immunotherapy
TiME analysis for Immunotherapy efficacy assessment
This machine is equipped with microdissection technology, which can separate highly active tumor cells and immune cells in TiME (CTM). Targeting drug-resistant populations, FISH is used to analyze the trends of miRNA mutation genes in CTM to precisely adjust treatment strategies.
Cell therapy
Tumor-infiltrating lymphocytes (TILs) isolation & initial expansionfor celltherapy
By dynamically tracking the tumor immune microenvironment, this system uses negative staining single-cell selection technology to identify effective immune cells (TILs) in the blood. Culture and cytotoxicity tests are then performed, which can serve as a prognostic indicator for evaluating cell therapy.
Target therapy
Liquid biopsy for drug
resistance of target therapy
The only commercially available ability to identify and capture circulating cancer cell masses (CTM), combined with single-cell NGS, or ddPCR), increases the resolution of traditional MRD using ctDNA detection and improves the sensitivity of tumor recurrence detection.
Combination immunotherapy
TiME analysis for Immunotherapy efficacy assessment
This machine is equipped with microdissection technology, which can separate highly active tumor cells and immune cells in TiME (CTM). Targeting drug-resistant populations, FISH is used to analyze the trends of miRNA mutation genes in CTM to precisely adjust treatment strategies.
Cell therapy
Tumor-infiltrating lymphocytes (TILs) isolation & initial expansionfor celltherapy
By dynamically tracking the tumor immune microenvironment, this system uses negative staining single-cell selection technology to identify effective immune cells (TILs) in the blood. Culture and cytotoxicity tests are then performed, which can serve as a prognostic indicator for evaluating cell therapy.
Target therapy
Liquid biopsy for drug
resistance of target therapy
The only commercially available ability to identify and capture circulating cancer cell masses (CTM), combined with single-cell NGS, or ddPCR), increases the resolution of traditional MRD using ctDNA detection and improves the sensitivity of tumor recurrence detection.
Combination immunotherapy
TiME analysis for Immunotherapy efficacy assessment
This machine is equipped with microdissection technology, which can separate highly active tumor cells and immune cells in TiME (CTM). Targeting drug-resistant populations, FISH is used to analyze the trends of miRNA mutation genes in CTM to precisely adjust treatment strategies.
Cell therapy
Tumor-infiltrating lymphocytes (TILs) isolation & initial expansionfor celltherapy
By dynamically tracking the tumor immune microenvironment, this system uses negative staining single-cell selection technology to identify effective immune cells (TILs) in the blood. Culture and cytotoxicity tests are then performed, which can serve as a prognostic indicator for evaluating cell therapy.
The best total solution for
physicians, hospitals, laboratories, and cell therapy companies
We can be
For doctors
a powerful tool can be used to diagnose cancer, guide treatment and predict patient survival.
For cell therapy companies
the secret weapon in the fight against cancer and improve treatment efficacy.
For GTP lab
a useful tool for more accurate, rapid, and high-throughput analysis in Single-cell multi-omics.
For LDT laboratories or hospitals
For LDT laboratories or hospitals
Product application-
Cancer treatment tracking
Disseminated Tumor Cells (DTCs) or circulating tumor microembolus (CTM) detection by liquid biopsy
Hospitals/Clinics/Laboratory/LDT Laboratories
Monitor treatment outcomes and identify any changes of TiME(CTM) in cancer through our AI-image scans, cytokine tests, and patient-reported data. It can help doctors track treatment outcomes, relapse, and drug resistance over 12 months.
If the cellular and molecular properties of the metastatic are seed the same across different tumor types and metastatic sites, a lineage analysis technique are required to quantify the fraction of single-cell versus multicellular immune cell and tumor microenvironment analyses to determine their molecular properties. To provide a total solution, we are accelerating the discovery of identification & pathogenesis in reproductive medicine and oncology by revealing the true functional biology of every pati
Longitudinal immune monitoring of patient’s TiME
Single cell NGS of tumor cells or immune cells in Circulating tumor microemboli (CTM) be used to predict the metastatic cascade of cancer in the blood by identifying the tumor immune-microenvironment (TiME). Through single-cell multiomics analysis, we can provide immune profiling of CTM and identify biomarkers for targeted drug selection.
Product application-Immune-cell therapy
One-Stop Service Business model
Service for cell and gene therapy CDMO and CRO companies.
Sorting the TILs from blood cocultured with CD8+ T cells isolated from tissue( if needed)
Co-cultured with primary cancer cells or CTM to dynamically monitor cytotoxicity efficacy
Let’s Start with the Right Cell.
Product : CIK stimulated reagent
Can save the cost of ineffective drug consumption USD 3.5~5.0 B (SOM:0.68B, SAM:3.6B, TAM:60B) can find out the significant inhibitor to improve anti-PD-1/PD-L1 immunotherapy (5K USD/M) by switching cold into hot tumors for the raising of ORR/PSF
Services: Immune functional assays
Test submission is initiated by a practicing physician
Assessment of Suitability for Immune Cell Therapy
Capture and Initial Cultivation of Target Immune Cells
Large-Scale Cell Culture and Processing
Cell Product Contract Manufacturing and Labeling
Test submission is initiated by a practicing physician
Assessment of Suitability for Immune Cell Therapy
Capture and Initial Cultivation of Target Immune Cells
Large-Scale Cell Culture and Processing
Cell Product Contract Manufacturing and Labeling
Can creating a USD 1.2 B minimal residual disease testing market (SOM:0.16B, SAM:0.8B, TAM:12.2B) Solve the unmet need that 30-40% of cancer patients can assist the personalized treatment selection by MRD (1-3K per time) of adjuvant tx improves the 5-year survival rate, going from 25% to 40%.
cytoTiME
A precision medicine platform for dynamic monitoring of tumor inflamed microenvironment (TiME) and immunotherapy response prediction
One Liquid Biopsy Report Reveals the Best Fit: Targeted, Immuno-, or Cell Therapy
Case Study
CellEnvision
Collect blood from
immunotherapy responders
Collect patient’s Blood-TILs
Expand Blood-TILs and collect exosomes
Co-culture exosomes with
patient’s CTM for efficacy testing
Total: 21 d
Conventional
Collect blood from
immunotherapy responders
Collect patient’s CIKs
Administer CIK cells and validate in vivo efficacy
Expand effective CIK cells and
collect exosomes
Total: 6~10 w
CTM-TiME
Unlocking Immune Precision in Cancer Therapy
Mutation + Tumor Cell Ratio
Targeted Therapy Selection
Blood-Derived TIL Selection
Immunotherapy Prognosis
Mutation + Tumor Cell Ratio
Cell Therapy Screening
- CTM-TiME: Non-invasive Blood-Based Tumor Microenvironment Profiling
- Supports Selective Immune Cell Expansion: 10⁷ Cells in Just 21 Days
- Real-Time Disease Tracking via Repeat Blood Tests — No More Waiting for Imaging
- Live Cell-Based Drug Testing with up to 90% Accuracy— 20–40% Higher Than Conventional Methods